Tempus AI Inc Earnings: Beat on EPS Despite Revenue Miss
Tempus AI Inc (TEM) reported mixed first-quarter results on May 5, 2026, beating earnings expectations while falling short on revenue. The company posted an adjusted loss of $0.13 per share versus the consensus estimate of a $0.19 loss, representing a 32.82% positive surprise.
The $0.13 per share loss marked a significant improvement from analyst expectations of $0.19, delivering $0.06 better than anticipated. This 32.82% earnings beat demonstrates better-than-expected cost management and operational efficiency during the quarter.
Revenue came in at $348.12 million, missing the consensus estimate of $348.91 million by $790,000, or 0.23%. The $348.12 million in quarterly revenue represents the company’s performance across its AI-driven precision medicine platform and data analytics services.
The earnings beat of 32.82% offset the modest revenue shortfall of 0.23%, suggesting Tempus AI maintained strong margin discipline while navigating competitive market conditions. The $0.06 per share outperformance on earnings indicates effective expense management despite the slight revenue miss of $790,000.
Why the EPS beat matters more than the revenue miss
The 0.23% revenue miss is statistically inside the rounding error of analyst estimates — a $790,000 shortfall on a $348.91 million base is well within the universe of normal sell-side dispersion. The 32.82% EPS beat, by contrast, is a different signal: it shows the company is reaching operating-leverage milestones that Wall Street has not yet modeled into its forecast. For a late-stage growth platform like Tempus AI, where consensus losses have historically been wider than realized losses, that gap is the single most important variable for the stock.
Where the revenue comes from
Tempus AI’s top line is a mix of two businesses. The larger segment is data and services, where pharmaceutical and biotech customers pay the company to run multi-omic sequencing, AI-based patient stratification, and real-world evidence queries against Tempus’s library of de-identified clinical and molecular records. The smaller but faster-growing segment is clinical care, where oncologists and pathologists order the company’s AI-assisted molecular profiling as part of patient treatment. The May 5 print suggests both lines continued to grow, but with the data services side carrying the disproportionate share of growth — consistent with what management telegraphed on the prior call about enterprise contract renewals.
Competitive landscape
Tempus AI competes on the data side with Caris Life Sciences, Foundation Medicine (a Roche subsidiary), and Guardant Health, and on the AI analytics side with a long tail of smaller startups. The structural advantage Tempus leans on is its multimodal data library: linked DNA, RNA, imaging, and clinical-outcome records on more than a million patients. Replicating that asset is the actual moat; the AI models on top of it are increasingly commoditized. That is why CFO discipline on the EPS line matters — investors are underwriting the data asset, not the model weights.
What to watch next
Three signals will move the stock into the Q2 print. First, the gross margin trajectory — sequencing reagent costs have eased, and the bull case is that gross margin steps up as the data library amortizes across more enterprise contracts. Second, net revenue retention: anything above 110% indicates existing customers are expanding their spend, which is the leading indicator for the topline turning back to consensus. Third, the trajectory of clinical-care order volume, which is the segment that connects the data asset to the patient end-market and is the most direct read on physician adoption.
This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.